🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,99 USD

Máx. histórico

178,74

2143 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,38%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+2,43%

Cierre anterior

18,54

Rango de hoy

18,52 – 19,26

Volumen hoy

1.328.200

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 23 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/03/2002 56,22 60,00 55,56 59,34 +6,69% 7,90% 29.783
28/02/2002 58,68 58,80 55,50 55,62 -3,13% 5,62% 17.117
27/02/2002 59,40 59,88 56,82 57,42 -3,24% 5,15% 22.333
26/02/2002 57,24 59,40 56,46 59,34 +2,59% 5,14% 20.217
25/02/2002 58,08 58,20 56,10 57,84 -0,10% 3,62% 24.867
22/02/2002 58,50 59,34 55,80 57,90 -1,93% 6,05% 24.000
21/02/2002 60,18 60,18 58,80 59,04 -1,89% 2,29% 11.100
20/02/2002 59,40 61,26 58,50 60,18 +2,03% 4,65% 26.500
19/02/2002 66,72 66,78 58,50 58,98 -12,39% 12,41% 41.450
15/02/2002 64,80 69,00 63,60 67,32 +0,99% 8,33% 28.567
14/02/2002 71,64 71,76 66,60 66,66 -7,03% 7,20% 26.133
13/02/2002 68,34 72,00 68,22 71,70 +4,92% 5,53% 31.300
12/02/2002 61,86 68,34 60,60 68,34 +8,48% 12,51% 26.283
11/02/2002 62,70 64,08 61,44 63,00 +0,00% 4,21% 13.267
08/02/2002 58,80 63,00 57,60 63,00 +7,69% 9,18% 27.833
07/02/2002 60,00 60,12 57,60 58,50 -2,60% 4,20% 24.183
06/02/2002 62,58 63,00 59,04 60,06 -2,53% 6,33% 24.417
05/02/2002 60,90 63,00 59,94 61,62 -0,29% 5,02% 24.967
04/02/2002 69,00 69,00 60,90 61,80 -11,97% 11,74% 17.750
01/02/2002 67,02 70,50 66,96 70,20 -0,09% 5,28% 18.433
31/01/2002 66,00 71,04 65,16 70,26 +6,65% 8,91% 32.783
30/01/2002 61,86 66,00 57,78 65,88 +6,60% 13,29% 65.883
29/01/2002 65,76 66,54 61,50 61,80 -6,36% 7,66% 19.550
28/01/2002 63,06 66,84 63,00 66,00 +3,77% 6,09% 38.267
25/01/2002 67,56 67,56 60,00 63,60 -6,61% 11,19% 76.867
24/01/2002 73,20 74,40 67,26 68,10 -6,66% 9,75% 37.517
23/01/2002 72,60 75,24 67,20 72,96 +2,18% 11,07% 57.333
22/01/2002 79,20 81,00 70,20 71,40 -8,25% 13,64% 74.500
18/01/2002 74,64 78,00 74,28 77,82 +4,18% 4,98% 55.433
17/01/2002 73,80 75,00 73,50 74,70 +1,97% 2,03% 20.117